Loading news...
Rocket Pharmaceuticals, Inc. (RCKT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Rocket Pharmaceuticals reports narrower-than-estimated Q4 loss. The company provides key updates on its pipeline candidates.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT - Get Free Report) has been given an average recommendation of "Hold" by the seventeen research firms that are presently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the fourth quarter and year ended December 31, 2025. “In 2025, we strengthened Rocket's leadership in cardiovascular gene therapy, supported by more than five years of clinical experience in Danon disease and cont.
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the TD Cowen 46th Annual Health Care Conference and Leerink Partners Global Healthcare Conference in Boston and Miami, respectively. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat and manag.
Shares of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT - Get Free Report) have received a consensus rating of "Hold" from the seventeen analysts that are presently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and eight have issued a buy recommendation
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT - Get Free Report)'s stock price passed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $3.43 and traded as high as $3.89. Rocket Pharmaceuticals shares last traded at $3.72, with a volume of 2,411,606 shares trading hands. Wall Street
Rocket Pharmaceuticals, Inc. (RCKT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
At the start of 2025, the stock market appeared unstable as most major assets were, seemingly, very overvalued. Despite this, there was no shortage of opportunities for savvy investors to find undervalued, cheap stocks that enabled them to turn a $1,000 into $10,000 of profit.
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the 44th Annual J.P. Morgan Healthcare Conference, in San Francisco. Gaurav Shah, M.D., Chief Executive Officer, is scheduled to present on Wednesday, January 14, at 11:15 a.m. PT and host investor meetings throughout th.
Rocket Pharmaceuticals is rated Buy with a $17 price target, reflecting a deep disconnect between intrinsic value and current valuation. RCKT's bullish thesis hinges on a high-probability LAD-1 approval in March 2026 and the pivotal Danon's disease trial resuming with an amended, safer protocol. Risk-adjusted DCF values Danon's and LAD-1 programs at ~$700M, far exceeding the current $151M EV, even under conservative or bear-case assumptions.
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the 8th Annual Evercore Healthcare Conference in Miami. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat on Tuesday, December 2, at 7:55 a.m. ET and host investor meetings. A webcast of the p.
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the third quarter ending September 30, 2025. “During the third quarter, we maintained disciplined execution and sharpened our strategic focus on Rocket's AAV cardiovascular gene therapy portfolio,” said Gaurav Sha.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Rocket (RCKT) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Rocket securities between February 27, 2025 to May 26, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Rocket Pharmaceuticals surges as the FDA accepts its resubmitted BLA for Kresladi, a gene therapy targeting the rare LAD-I disorder.
On Tuesday, the U.S. Food and Drug Administration (FDA) accepted Rocket Pharmaceuticals, Inc.'s (NASDAQ:RCKT) resubmission of the Biologics License Application (BLA) for Kresladi (marnetegragene autotemcel; marne-cel), a lentiviral vector (LV)-based investigational gene therapy for severe Leukocyte Adhesion Deficiency-I (LAD-I).
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the Biologics License Application (BLA) for KRESLADI™ (marnetegragene autotemcel; marne-cel), a lentiviral vector (LV)-based investigational gene therapy for severe Leukocyte.
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that on October 6, 2025, the Compensation Committee of Rocket's Board of Directors approved the grant of inducement equity incentive awards to its newly-hired Chief Medical Officer, Dr. Syed Rizvi. The inducement awards consist of (i) a nonstatutory stock o.
Rocket Pharmaceuticals said on Friday that it has withdrawn its application for U.S approval of its experimental gene therapy for a rare inherited blood disorder.
NEW YORK , Sept. 19, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) breached their fiduciary duties to shareholders.